MODIFIED NUCLEIC ACIDS, AND ACUTE CARE USES THEREOF
The invention provides compositions and methods for effecting wound healing in a mammal, where the compositions include therapeutic mRNA which incorporate modified nucleosides and nucleotides.
1 . A method of treating a mammalian subject in need thereof comprising administering an mRNA encoding a polypeptide of interest.
2 . The method of claim 1 , wherein the mammalian subject is suffering from or is at risk of developing an acute or life-threatening disease or condition.
3 . The method of claim 2 , wherein the mammalian subject is suffering from a traumatic injury.
4 . The method of claim 2 , wherein the polypeptide of interest accelerates wound healing.
5 . The method of claim 1 , wherein the mammalian subject is suffering from a bacterial infection and wherein the polypeptide of interest is an anti-microbial peptide (AMP).
6 . The method of claim 5 , wherein the polypeptide of interest is an anti-viral.
7 . The method of claim 1 , wherein the polypeptide of interest is a cytokine.
8 . The method of claim 7 , wherein the mRNA is formulated and wherein the formulation is selected from the group consisting of lipid nanoparticle, polymer, hydrogel and surgical sealant.
9 . The method of claim 8 , wherein the formulated mRNA is administered to the mammalian subject by a route selected from the group consisting of transdermal, epicutaneous, intradermal, subcutaneous, intravenous, intramuscular, transdermal, topical, and systemic.
10 . The method of claim 9 , wherein the formulated mRNA is administered transdermally to the mammalian subject.
11 . The method of claim 9 , wherein the formulated mRNA is administered topically to the mammalian subject.
12 . The method of claim 8 , wherein the formulated mRNA is administered to the mammalian subject using bandages or dressings comprising the formulated mRNA.
13 . The method of claim 1 , wherein the polypeptide of interest is a protein expressed by macrophages.
14 . The method of claim 13 , wherein the mRNA is formulated and wherein the formulation is selected from the group consisting of lipid nanoparticle, polymer, hydrogel and surgical sealant.
15 . The method of claim 14 , wherein the formulated mRNA is administered to the mammalian subject by a route selected from the group consisting of transdermal, epicutaneous, intradermal, subcutaneous, intravenous, intramuscular, transdermal, topical, and systemic.
16 . The method of claim 14 , wherein the formulated mRNA is administered to the mammalian subject using bandages or dressings comprising the formulated mRNA.
17 . The method of claim 1 , wherein the polypeptide of interest is an angiogenic growth factor.
18 . The method of claim 17 , wherein the mRNA is formulated and wherein the formulation is selected from the group consisting of lipid nanoparticle, polymer, hydrogel and surgical sealant.
19 . The method of claim 18 , wherein the formulated mRNA is administered to the mammalian subject by a route selected from the group consisting of transdermal, epicutaneous, intradermal, subcutaneous, intravenous, intramuscular, transdermal, topical, and systemic.
20 . The method of claim 18 , wherein the formulated mRNA is administered to the mammalian subject using bandages or dressings comprising the formulated mRNA.